- Reuters•1 hour ago
U.S. health regulators on Thursday approved a drug developed by Merck KGaA and Pfizer Inc that helps the immune system to fight a rare form of skin cancer once it has spread to other parts of the body. The Food and Drug Administration said it approved Bavencio, known chemically as avelumab, to treat metastatic Merkel cell carcinoma (MCC) in patients 12 years and older. Bavencio belongs to a new class of oncology drugs called PD-L1 inhibitors that block a mechanism tumors use to evade detection from the immune system.
- Investopedia•6 hours ago
With all eyes focused on the Dow's recent rally, there is one investment strategy that couldn't care less.
- Investopedia•8 hours ago
A recent study has put a big question mark on the efficacy and safety of the most popular and established drug for sciatica pain
PFE : Summary for Pfizer, Inc. Common Stock - Yahoo Finance
Pfizer Inc. (PFE)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||34.23 - 34.56|
|52 Week Range||29.41 - 37.39|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||29.23|
|Dividend & Yield||1.28 (3.74%)|
|1y Target Est||N/A|